Explore the Global Brain Tumor Drugs Market — Key Trends, Regional Growth, Top Players, and 10-Year Forecast from 2026 to 2036

Future Market Insights

Brain Tumor Drugs Market

Key Insight

Demand for brain tumor drugs will increase through 2036, with temozolomide at 36.8% of the drug class in 2026. The market was valued at USD 3.28 billion in 2025 and is expected to be worth USD 8.29 billion by 2036, creating an incremental opportunity of USD 4.85 billion.

May 26, 2026

Anurag Sharma

302 Pages

Cite this Report

Brain Tumor Drugs Market

https://www.futuremarketinsights.com/reports/brain-tumor-drugs-market

License

Buy Now

Summary ToC Infographics Companies

Key Players

The Vanguard Group
Amgen
Antisense Pharma
BlackRock
Bayer
BeiGene
Bristol-Myers Squibb
Dr. Reddy’s Laboratories
Eli Lilly and Company
Karyopharm Therapeutics
Merck KGaA
Novartis
Roche

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Brain Tumor Drugs Market

Key Players

Similar Industry Reports